The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro

Japanese Journal of Cancer Research

Volumn 88, Issue 12, 1997, Pages 1211-1217

  Takahashi, Toshiaki ^a   Fujiwara, Yasuhiro ^a   Yamakido, Michio ^a   Katoh, Osamu ^b   Watanabe, Hiromitsu ^b   Mackenzie, Peter I ^c  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

CPT 11; Drug resistance; Lung cancer; SN 38; UDP glucuronosyltransferase

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DRUG METABOLIZING ENZYME; GLUCURONOSYLTRANSFERASE; MESSENGER RNA;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG INACTIVATION; DRUG RESISTANCE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG CANCER; NORTHERN BLOTTING; PRIORITY JOURNAL;

EID: 0031473370     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1997.tb00351.x     Document Type: Article

References (32)

1. Burchell, B., Nebert, D. W., Nelson, D. R., Bock, K. W., Iyanagi, T., Jansen, P. L. M., Lancet, D., Mulder, G. J., Chowdhury, J. R., Siest, G., Tephly, T. R. and Mackenzie, P. I. The UDP glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence. DNA Cell Biol., 10, 487-494 (1991).
2. Miners, J. O. and Mackenzie, P. I. Drug glucuronidation in humans. Pharmacol. Ther., 51, 347-369 (1991).
3. Clarke, D. J. and Burchell, B. The uridine diphosphate glucuronosyltransferase multigene family: function and regulation. In "Handbook of Experimental Pharmacology," ed. F. C. Kaufman, Vol. 112, pp. 3-43 (1994). Springer Verlag, Heidelberg.
4. Gessner, T., Vaughan, L. A., Beehler, B. C., Bartels, C. J. and Baker, R. M. Elevated pentose cycle and glucuronyl-transferase in daunorubicin-resistant P388 cells. Cancer Res., 50, 3921-3927 (1990).
5. Franklin, T. J., Jacobs, V., Jones, G., Ple, P. and Bruneau, P. Glucuronidation associated with intrinsic resistance to mycophenolic acid in human colorectal carcinoma cells. Cancer Res., 56, 984-987 (1996).
6. Lavelle, F., Bissery, M. C., Andre, A., Roquet, F. and Riou, J. F. Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin. Oncol., 23 (Suppl. 3), 11-20 (1996).
7. Dancey, J. and Eisenhauer, E. A. Current perspectives on camptothecins in cancer treatment. Br. J. Cancer, 74, 327-338 (1996).
8. Rivory, L. P., Bowles, M. R., Robert, J. and Pond, S. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem. Pharmacol., 52, 1103-1111 (1996).
9. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H. and Sato, K. Intracelluar roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res., 51, 4187-4191 (1991).
10. Atsumi, R., Suzuki, W. and Hakusui, H. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica, 21, 1159-1169 (1991).
11. Lokiec, F., Du Sorbier, B. M. and Sanderink, G. J. Irinotecan (CPT-11) metabolism in human bile and urine. Clin. Cancer Res., 2, 1943-1949 (1996).
12. Haaz, M. C., Rivory, L. P. and Robert, J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome p-450 3A (CYP3A) and drug interaction. Proc. Am. Asso. Cancer Res., 38, 17 (1997).
13. Pommier, Y., Tanizawa, A., Okada, K. and Andoh, T. Cellular determinants of sensitivity and resistance to camptothecins. In "Camptothecins: New Anticancer Agents," ed. M. Potmesil and H. Pinedo, pp. 123-138 (1995). CRC Press, Boca Raton.
14. Iyer, L., King, C., Tephly, T. and Ratain, M. J. UGT isoform 1.1 (UGT* 1.1) glucuronidates SN-38, the active metabolite of irinotecan. Proc. Am. Soc. Clin. Oncol., 16, 201a (1997).
15. Kanzawa, F., Sugimoto, Y., Minato, K., Kasahara, K., Bungo, M., Nakagawa, K., Fujiwara, Y., Liu, L. F. and Saijo, N. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res., 50, 5919-5924 (1990).
16. Kubota, N., Kanzawa, F., Nishio, K., Takeda, Y., Ohmori, T., Fujiwara, Y., Terashima, Y. and Saijo, N. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochem. Biophys. Res. Commun., 188, 571-577 (1992).
17. Yokoi, T., Narita, M., Nagai, E., Hagiwara, H., Aburada, M. and Kamataki, T. Inhibition of UDP-glucuronosyl-transferase by aglycons of natural glucuronides in kampo medicines using SN-38 as a substrate. Jpn. J. Cancer Res., 86, 985-989 (1995).
18. Sumiyoshi, H., Fujiwara, Y., Ohune, T., Yamaoka, N. and Yamakido, M. High-performance liquid chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasma. J. Chromatogr. B, 670, 309-316 (1995).
19. Kanzawa, F., Nishio, K., Kubota, N. and Saijo, N. Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB. Cancer Res., 55, 2806-2813 (1995).
20. Mackenzie, P. I., Gonzalez, F. J. and Owens, I. S. Cloning and characterization of DNA complementary to rat liver UDP-glucuronosyltransferase mRNA. J. Biol. Chem., 259, 12153-12160 (1984).
21. Chomczynski, P. and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal. Biochem., 162, 156-159 (1987).
22. Ohashi, N., Fujiwara, Y., Yamaoka, N., Katoh, O., Satow, Y. and Yamakido, M. No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer. Jpn. J. Cancer Res., 87, 1280-1287 (1996).
23. Ritter, J. K., Chen, F., Sheen, Y. Y., Tran, H. M., Kimura, S., Yeatman, M. T. and Owens, I. S. A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxy termini. J. Biol. Chem., 259, 3257-3261 (1992).
24. Sumiyoshi, H., Fujiwara, Y., Ohashi, N., Egusa, Y., Yamaoka, N. and Yamakido, M. Clinical pharmacological evaluation of CPT-11 and cisplatin (CDDP) in patients with small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol., 14, 457 (1995).
25. Toussaint, C., Albin, N., Massaad, L., Grunenwald, D., Parise, O., Jr., Morizet, J., Gouyette, A. and Chabot, G. G. Main drug- and carcinogen-metabolizing enzyme systems in human non-small cell lung cancer and peritumoral tissues. Cancer Res., 53, 4608-4612 (1993).
26. Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E. and Ratain, M. J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res., 54, 3723-3725 (1994).
27. Rivory, L. P. and Robert, J. Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother. Pharmacol., 36, 176-179 (1995).
28. Gupta, E., Mick, R., Ramirez, J., Wang, X., Lestingi, T. M., Yokes, E. E. and Ratain, M. J. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J. Clin. Oncol., 15, 1502-1510 (1997).
29. Sridhara, R., Fujiwara, Y., Egorin, M. J. and Chabot, G. G. Population pharmacokinetics (PK) in two treatment schedules of irinotecan (CPT-11) and metabolite (SN-38). Proc. Am. Soc. Clin. Oncol., 16, 206a (1997).
30. Fujiwara, Y., Egorin, M. J., Reyna, S., Tait, N., van Echo, D. A., Yamakido, M. and Sridhara, R. Population pharmacokinetics (PK) of irinotecan (CPT-11) and metabolites. Proc. Am. Soc. Clin. Oncol., 16, 237a (1997).
31. Jansen, P. L. Genetic diseases of bilirubin metabolism: the inherited unconjugated hyperbilirubinemias. J. Hepatol., 25, 398-404 (1996).
32. Monaghan, G., Ryan, M., Seddon, R., Hume, R. and Burchell, B. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet, 347, 578-581 (1996).